SCHEMBL5134933

SCHEMBL5134933

CCCCn1c(CN(CCc2ccc(OC)cc2OC)Cc2ccc3c(c2)OCO3)cnc1-c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.49
TP53 P04637 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HTR2A P28223 8/20 0.45
HTR2C P28335 8/20 0.45
HTR2B P41595 8/20 0.45
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
ADRB1 P08588 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
DRD2 P14416 1/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41
DRD1 P21728 1/20 0.41
DRD4 P21917 1/20 0.41
SLC6A2 P23975 1/20 0.41
ADRA1D P25100 1/20 0.41
HTR1D P28221 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137546 0.94 HTR2A (0.49) C5AR1TP53SMN1; SMN2HTR2AHTR2C
SCHEMBL5135206 0.93 TP53 (0.45) C5AR1TP53SMN1; SMN2HTR2AHTR2C
SCHEMBL5136131 0.92 C5AR1 (0.52) C5AR1TP53SMN1; SMN2HTR2AHTR2C
SCHEMBL5137845 0.90 HTR2A (0.54) C5AR1TP53SMN1; SMN2HTR2AHTR2C
SCHEMBL5137323 0.89 C5AR1 (0.51) C5AR1TP53SMN1; SMN2HTR2AHTR2C
SCHEMBL5136237 0.88 C5AR1 (0.55) C5AR1TP53SMN1; SMN2HTR2AHTR2C
SCHEMBL5137595 0.88 TP53 (0.55) C5AR1TP53SMN1; SMN2HTR2AHTR2C
SCHEMBL5137371 0.88 C5AR1 (0.49) C5AR1TP53SMN1; SMN2HTR2AHTR2C
SCHEMBL5134549 0.88 C5AR1 (0.50) C5AR1TP53SMN1; SMN2HTR2AHTR2C
SCHEMBL5135001 0.88 TP53 (0.54) C5AR1TP53SMN1; SMN2HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed